ALTEOGEN Inc. (KOSDAQ:196170)

South Korea flag South Korea · Delayed Price · Currency is KRW
333,500
-10,500 (-3.05%)
May 28, 2025, 3:30 PM KST
75.71%
Market Cap 17.77T
Revenue (ttm) 151.65B
Net Income (ttm) 124.46B
Shares Out 53.30M
EPS (ttm) 2,331.25
PE Ratio 143.06
Forward PE 710.96
Dividend n/a
Ex-Dividend Date n/a
Volume 344,117
Average Volume 339,518
Open 345,500
Previous Close 344,000
Day's Range 330,000 - 345,500
52-Week Range 171,200 - 459,500
Beta 1.36
RSI 44.99
Earnings Date May 15, 2025

About ALTEOGEN

ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the tre... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 155
Stock Exchange KOSDAQ
Ticker Symbol 196170
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.